Market News

Curaleaf International to Present Positive Clinical and Pre-Clincial Research

Clinical study demonstrates significant improvement in pain

Curaleaf International (the "Company") part of Curaleaf Holdings (CNSX:CURA), Europe's largest vertically integrated cannabis company, is pleased to announce that Chief Scientific Officer, Dr Barbara Pacchetti will present research on one clinical study and three preclinical studies at a leading conference on medical cannabis on 21-22 October 2022. These papers have been peer-reviewed and selected for presentation and publication in the official Conference Proceedings Journal Medical Cannabis and Cannabinoids (Karger Publishers, Basel, Switzerland).

Research to be presented from the clinical study focuses on the delivery of a cannabidiol (CBD) preparation to patients with Vestibulodynia (VBD) which is a prevalent form of chronic genital pain in women with no standard treatment. The study, a randomized placebo control study, of 60 patients showed significant improvement of outcomes on pain, dyspareunia (genital pain before, during or after sex), pelvic muscular tone and neurometer parameters, which highlights implications for its anti-inflammatory, anti-nociceptive action and anti-neuropathic therapeutic potential. The title of the paper is: Transmucosal delivery of cannabidiol using vestibular electroporation in patients with vestibulodynia: interim analysis of a randomized, blinded prospective trial. The co-authors are F. Murina, Prof. MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.

Preclinical research to be presented focuses on the potential positive impact of CBD on the treatment of several psychiatric disorders and inflammatory disease, the therapeutic potential for migraine pain and trigeminal excitability related to migraine. For further information on the preclinical research to be presented, please see the footnote at the end of this announcement. *

Dr. Barbara Pacchetti, Chief Scientific Officer at Curaleaf International, commented, "We are very pleased with the findings from our clinical study on the delivery of CBD to treat patients with VBD, and that it is showing a significant improvement in pain outcomes for patients. Additionally, the preclinical research on the therapeutic potential of CBD to treat a number of other indications is also encouraging and I look forward to presenting this to the scientific community and to furthering our research into the potential for CBD. We believe the growth and understanding of medical cannabis must be underpinned by the most robust science. Curaleaf International is working with some of the world's leading academic institutions such as Imperial College, the University of Milan and University of Insubria and we look forward to further updating all stakeholders with our progress."

To learn more about the conference please visit the conference website .

About Curaleaf International
Curaleaf International (formerly EMMAC Life Sciences Group) is Europe's largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, Curaleaf International's vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021.

For more information about Curaleaf International, please visit:

About Curaleaf Holdings
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, and Grassroots provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States, Curaleaf currently operates in 21 states with 144 dispensaries, 26 cultivation sites, and employs over 6,000 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit .

*Details on the preclinical studies
Cannabidiol (CBD) is considered a valuable potential treatment for several psychiatric disorders. This preclinical study demonstrates, for the first time, that CBD is detected in the plasma and medial prefrontal cortex (mPFC), following single or repeated treatment at therapeutical doses, with a specific dose-response profile. CBD significantly modulates brain-derived neurotrophic factor (BDNF) expression, a neurotrophin critical for synaptic plasticity, following a brain specific anatomical pattern. This modulatory effect on BDNF might be functionally relevant and represent added value for the potential therapeutic role of CBD in psychiatric disorders.

(Title and Authors: Cannabidiol exposure modulated the BDNF system in the rat cortico-striatal circuitry – F. Mottarlini, M. Fumagalli, F. Castillo-Diaz, S. Piazza, G. Targa, E. Sangiovanni, B. Pacchetti, M.H. Sodergren, M. Dell'Agli, F. Fumagalli and L. Caffino)

Polymorphonuclear leukocytes (PMN) are the first immune cell to be recruited into inflammatory sites, and cannabidiol (CBD) extensively affects their functions. This study confirmed the anti-inflammatory activity of CBD on some PMN functions observed in a previous study. Results indicate that CBD counteracts the effects of priming on key functions such as migration and ROS production, strengthening its therapeutic potential in inflammatory disease.

(Title and Authors: Effects of cannabidiol on migration and reactive oxygen species production in bacterial lipopolysaccharide primed human polymorphonuclear leukocyte - F. Marino, E. Rasini, A. Luini, M. Legnaro, A. Gemma, B. Pacchetti, M. H. Sodergren, M. Cosentino)

Clinical and preclinical data have suggested a deregulation of the endocannabinoid system (ECS) in migraine pain and trigeminal excitability related to migraine. This in-vivo study evaluated and found key information on the accumulation of Cannabidiol (CBD) in brain areas that are involved in migraine pain in an animal model at therapeutical doses chronically, and evidenced that a single CBD administration may reduce trigeminal hyperalgesia in an animal model for migraine pain. The results suggested the capability of CBD to modulate migraine-related nociceptive transmission via specific central and peripheral regions.

(Title and Authors: Cannabidiol as a potential treatment for migraine: preliminary data in an animal model. R Greco, C Demartini, M Francavilla, M Palmisani, A M Zanaboni, R Marchiselli, S Facchetti, V Franco, B Pacchetti, C Tassorelli)

All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of Curaleaf International. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Curaleaf International assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Media enquiries:
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz
Tel: +44 (0) 20 7466 5000

News Provided by Business Wire via QuoteMedia

The Conversation (0)

Aurora Provides Update on Nasdaq Listing


Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced receipt of a notification letter (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") dated March 24, 2023 advising that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) as the bid price of the Company's listed securities had closed at less than US$1.00 per share over the last 30 consecutive business days (the "Minimum Bid Price Requirement") from February 8, 2023 to March 23, 2023 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
dollar sign with arrows pointing up

Cannabis Weekly Round-Up: US Sales to Reach US$35 Billion in 2023

US cannabis sales are now projected to cross US$35 billion in 2023 and reach US$71 billion per year by 2030.

Meanwhile, a leading multi-state operator (MSO) informed the market it will need more time to file its latest financial report.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less

Curaleaf Provides Update on 2022 Fourth Quarter and Full-Year Earnings Release and Earnings Call

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced that it will delay its fourth quarter and full year earnings release and conference call, which were originally scheduled for March 28, 2023 . Due to the complexities of converting three years of financials from IFRS to U.S. GAAP coinciding with year and quarter-end reporting, and the review of the treatment of various accounting matters, the Company requires additional time to complete its financial statements.  The Company expects to file its financial statements within the month of April, no later than the prescribed filing deadline provided for under applicable securities laws. The Company will announce the date of the release of its financial statements and an earnings conference call in a subsequent press release.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Goodness Growth Holdings to Report Fourth Quarter and Full Year 2022 Results on March 30, 2023

Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company focused on providing safe access, quality products and great value to its customers, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2022 on Thursday, March 30, 2023 after the market closes.

Goodness Growth management will host a conference call with the investment community the same day, at 4:30 p.m. ET (3:30 p.m. CT) to discuss its results. Interested parties may attend the conference call by dialing 1-888-414-4585 (Toll-Free) (US and Canada) or 1-646-960-0331 (Toll) (International) and referencing conference ID number 8663261.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Squeeze the Day! First Lemonnade Branded Dispensary Arrives In Michigan Bringing It's Sativa-Focused Family of Strains and Products

TerrAscend and Cookies Debut New Retail Concept in Center Line

TerrAscend Corp. ("TerrAscend" or the "Company") (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that its subsidiary, Gage Cannabis Co. ("Gage") will lead an exciting new era in cannabis retail with the grand opening of Lemonnade Center Line the first sativa-focused provisioning center in Michigan . Through its partnership with Cookies, a globally recognized cannabis brand, Gage will open a 4,600 square-foot retail store located at 24729 Sherwood Avenue in Center Line a suburb in the heart of Metro-Detroit, that will feature an exclusive selection of the most flavorful and uplifting sativa strains on the market. Lemonnade Center Line is open from 9:00 am to 9:00 pm daily.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Tinley's Provides Corporate Updates; Announces Cost Cutting Initiatives, Board & Management Changes

Tinley's Provides Corporate Updates; Announces Cost Cutting Initiatives, Board & Management Changes

The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB: TNYBF) ("Tinley's" or the "Company") provides update on the status of the previously announced decommissioning of its Long Beach manufacturing facility and relocation of its bottling and related assets to the new Blaze Life Holdings, LLC ("BLH") 45,000 square foot cannabis manufacturing and distribution facility located in Canoga Park, California, and on related measures being immediately implemented to facilitate the relocation including, but not limited to, substantive cost cutting initiatives and changes to the board and management teams.

Corporate Updates

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News